The BUOS are excited to announce the upcoming volume of our peer-reviewed journal, BUJO! If you're a student or junior doctor with a report, review or research in the field of ophthalmology, send us your submission now for a chance to get published!
๐๐ More details below ๐๐
โ Join us live on 27 July 2020
๐ ACST 12:30AM | AEST 1:00AM | PT 8:00AM | ET 11:00AM | BST 4:00PM | CEST 5:00PM | IST 8:30PM | CST, SST 11:00PM | AWST 11:00PM
โ Unable to attend the live event?
๐ป Register to watch on-demand ๐ https://t.co/0pxPPSdFJz
๐ฌ #RSMCOVIDConf
By 2 years of anti-VEGF treatment for AMD, ~60% of eyes have non-geographic atrophy, and by 3 more years, half of them develop geographic atrophy. https://t.co/VOkW71PDWS
Clinicians have warned that attendance rates have dropped dramatically for those needing urgent treatment for macular disease, as people are too scared to attend @Telegraph#SightLoss https://t.co/yUabw3Rgf5
Clinical Challenge: Near complete #visionloss and #headaches. Severe papilledema on exam. MRV shows filling defects of transverse sinuses. Next Step? https://t.co/QlQDHhMhSl
The BUOS are excited to announce the upcoming volume of our peer-reviewed journal, BUJO! If you're a student or junior doctor with a report, review or research in the field of ophthalmology, send us your submission now for a chance to get published!
๐๐ More details below ๐๐